Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent CB2 selective agonist (Ki = 3.4 nM), in water-soluble emulsion (for details see TocrisolveTM 100). Approx. 200-fold selective over CB1 receptors. Active in vivo, reducing spasticity in a murine model of multiple sclerosis.
JWH 133 available as a solid.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Baker et al (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 84 PMID: 10716447
Huffman et al (1999) 3-(1'-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg.Med.Chem. 7 2905 PMID: 10658595
Pertwee (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635 PMID: 10469884
Keywords: JWH 133 (in Tocrisolve 100), JWH 133 (in Tocrisolve 100) supplier, Potent, selective, CB2, agonists, water-soluble, emulsion, cannabinoids, Receptors, JWH133, cb2r, 1783, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for JWH 133 (in Tocrisolve™ 100) include:
Williams et al (2014) △(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection. Autophagy 9 369 PMID: 24562630
There are currently no reviews for this product. Be the first to review JWH 133 (in Tocrisolve™ 100) and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.